432 related articles for article (PubMed ID: 23425382)
1. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
Carmichael SJ; Day RO; Tett SE
Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
[TBL] [Abstract][Full Text] [Related]
2. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Jallouli M; Galicier L; Zahr N; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Le Thi Huong D; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Leroux G; Cohen-Bittan J; Sellam J; Mariette X; Blanchet B; Hulot JS; Amoura Z; Piette JC; Costedoat-Chalumeau N;
Arthritis Rheumatol; 2015 May; 67(8):2176-84. PubMed ID: 25989906
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
[TBL] [Abstract][Full Text] [Related]
4. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
[TBL] [Abstract][Full Text] [Related]
5. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Hammoud HA; Aymard G; Cacoub P; Francès C; Wechsler B; Huong du LT; Ghillani P; Musset L; Lechat P; Piette JC
Arthritis Rheum; 2006 Oct; 54(10):3284-90. PubMed ID: 17009263
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
7. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
[TBL] [Abstract][Full Text] [Related]
8. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels.
Jolly M; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin DL; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Hulot JS; Arora S; Amoura Z; Piette JC; Costedoat-Chalumeau N;
Lupus; 2016 Jun; 25(7):735-40. PubMed ID: 26876692
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
[TBL] [Abstract][Full Text] [Related]
13. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
Momose Y; Arai S; Eto H; Kishimoto M; Okada M
J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
[TBL] [Abstract][Full Text] [Related]
14. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
Yeon Lee J; Lee J; Ki Kwok S; Hyeon Ju J; Su Park K; Park SH
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):536-542. PubMed ID: 27390146
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Garg S; Unnithan R; Hansen KE; Costedoat-Chalumeau N; Bartels CM
Arthritis Care Res (Hoboken); 2021 May; 73(5):707-716. PubMed ID: 32004406
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
Balevic SJ; Cohen-Wolkowiez M; Eudy AM; Green TP; Schanberg LE; Clowse MEB
J Rheumatol; 2019 Jan; 46(1):57-63. PubMed ID: 30275257
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine: a multifaceted treatment in lupus.
Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
19. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
